期刊文献+

合并慢性肾功能衰竭三阴性乳腺癌患者术后行环磷酰胺联合紫杉类方案化疗的安全性分析 被引量:7

Safety analysis of postoperative cyclophosphamide combined with taxane chemotherapy in patients with triple-negative breast cancer and chronic renal failure
原文传递
导出
摘要 目的探讨合并慢性肾功能衰竭三阴性乳腺癌患者术后行环磷酰胺联合紫杉类方案化疗的安全性及合并症处理策略。方法回顾性分析2016年6月至2019年12月天津市人民医院收治的8例合并慢性肾功能衰竭三阴性乳腺癌患者的临床及随访资料。结果本组8例患者术后均行标准的环磷酰胺联合紫杉类方案化疗,其中5例为多西他赛75 mg/m^(2)+环磷酰胺600 mg/m^(2),3例为白蛋白紫杉醇260 mg/m^(2)+环磷酰胺600 mg/m^(2)。化疗过程中仅白细胞减少脱发及胃肠道反应等不良事件出现3~4级,发生率分别为25%.25%及12%。4例患者因不良反应调整了用药剂量。除1例患者放弃后续化疗外,其余患者均顺利完成4个周期的化疗。患者在化疗前平均血肌酐水平为(498±63)μmol/L,化疗后为(518±61)pumol/L,差异无统计学意义(t=-2.335,P>0.05)。结论合并慢性肾功能衰竭并非乳腺癌患者术后化疗的禁忌证,针对三阴性乳腺癌患者术后选择标准环磷酰胺联合紫杉类方案并适当调整药物剂量进行辅助化疗是安全的。 Objective To explore the safety of eyelophosphamide combined with taxane chemotherapy in triple-negative breast cancer patients with chronie renal failure and the management strategy of complications.Methods Data of 8 patients with triple-negative breast cancer and chronie renal failure adnmitted to our hospital from Jun 2016 to Dee 2019 were retrospectively analyzed.Results Eight patients received standard cyelophosphamide combined with taxane(TC regimen)chemotherapy after operation,5 of which received docetaxel 75 mg/m^(2)+cyclophosphamide 600 mg/m',and 3 received albumin paclitaxel 260 mg/m^(2)+ceyclophosphamide 600 mg/m^(2),during chemoherapy,only leukopenia,hair loss and gastrointestinal reactions oecurred in grades 3 to 4,and the ineidence was 25%,25%and 12%,respectively.Four patients adjusted the dosage due to adverse reactions.One patient quit,the remaining patients sesfully completed 4 eycles of chemotherapy.The average serum creatinine before chemotherapy was(498±63)μmol/L,and after chemotherapy,it was(518±61)μmo/L(t=-2.335,P>0.05).Conclusions Combined with chronie renal failure is not a contraindication to postoperative chemotherapy for patients with breast cancer.It is safe to choose standard TC regimen and adjust the dose of adjuvant chemotherapy for patients with triple-negative breast cancer.
作者 陶为杰 郝洁 高影 王首骏 解海 张振东 Tao Weijie;Hao Jie;Gao Ying;Wang Shoujun;Xie Hai;Zhang Zhendong(Department of Breast and Thyroid Surgery,Tianjin People's Hospital,Tianjin 300121.China)
出处 《中华普通外科杂志》 CSCD 北大核心 2021年第2期102-105,共4页 Chinese Journal of General Surgery
关键词 乳腺肿瘤 肾功能衰竭 慢性 环磷酰胺 药物疗法 联合 安全 Breast neoplasms Kidney failure,chronie Cyelophosphamide Dug therapy,comhination Safety
作者简介 通信作者:张振东,Email:zzdl9620810@sina.com,电话:022-27557171。
  • 相关文献

参考文献3

二级参考文献41

  • 1Cvetkovi'c RS,Scott LJ.Dexrazoxane:a review of its use for cardioprotection during anthracycline chemotherapy[J].Drugs,2005,65(7):1005-1024.
  • 2Barry E,Alvarez JA,Scully RE,et al.Anthracycline-induced cardiotoxicity:course,pathophysiology,prevention and management[J].Expert Opin Pharmacother,2007,8 (8):1039-1058.
  • 3Lipshultz SE,Lipsitz SR,Sallan SE,et al.Chronic progressive cardiac dysfunction years after doxorubicin therapy for childhood acute lymphoblastic leukemia[J].J Clin Oncol,2005,23(12):2629-2636.
  • 4Lipshultz SE,Colan SD,Gelber RD,et al.Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood[J].N EnglJ Med,1991,324(12):808-815.
  • 5Von Hoff DD,Layard MW,Basa P,et al.Risk factors for doxorubicin-induced congestive heart failure[J].Ann Intern Med,1979,91(5):710-717.
  • 6Swain SM,Whaley FS,Ewer MS,et al.Congestive heart failure in patients treated with doxorubicin:a retrospective analysis of three trials[J].Cancer,2003,97 (11):2869-2879.
  • 7Keefe DL.Anthracycline-induced cardiomyopathy[J].Semin Oncol,2001,28(4 Suppl 12):2-7.
  • 8Ganame J,Claus P,Uyttebroeck A,et al.Myocardial dysfunction late after low-dose anthracycline treatment in asymptomatic pediatric patients[J].J Am Soc Echocardiogr,2007,20 (12):1351-1358.
  • 9Robert J,Morvan VL,Smith D,et al.Predicting drug response and toxicity based on gene polymorphisms[J].Crit Rev Oncol Hematol,2005,54(3):171-196.
  • 10Lipshultz SE,Rifai N,Sallan SE,et al.Predictive value of cardiac troponin T in pediatric patients at risk for myocardial injury[J].Circulation,1997,96 (8):2641-2648.

共引文献260

同被引文献115

引证文献7

二级引证文献15

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部